MATTHEW WANAT to Medicare Part C
This is a "connection" page, showing publications MATTHEW WANAT has written about Medicare Part C.
Connection Strength
0.057
-
Impact of adherence on the cost-effectiveness of apixaban and rivaroxaban in stroke prevention among patients with atrial fibrillation in the United States. Expert Rev Pharmacoecon Outcomes Res. 2025 Jan; 25(1):63-70.
Score: 0.057